Correction: Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Affiliations

¹ Department of Radiation Medicine and Applied Sciences, University of California San Diego Medical Center, La Jolla, California, USA
² Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
³ Department of Biostatistics and Bioinformatics, NRG Oncology, Clinical Trial Development Division, Buffalo, New York, USA.
⁴ Biopathology Center, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA.
⁵ Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Published Erratum

Jyoti Mayadev et al. Int J Gynecol Cancer. 2020 Jul.

. 2020 Jul;30(7):1084.

doi: 10.1136/ijgc-2019-001012corr1. Epub 2020 May 4.

¹ Department of Radiation Medicine and Applied Sciences, University of California San Diego Medical Center, La Jolla, California, USA
² Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
³ Department of Biostatistics and Bioinformatics, NRG Oncology, Clinical Trial Development Division, Buffalo, New York, USA.
⁴ Biopathology Center, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA.
⁵ Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

No abstract available

Erratum for

Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Mayadev J, et al. Int J Gynecol Cancer. 2020 May;30(5):701-704. doi: 10.1136/ijgc-2019-001012. Epub 2019 Dec 22. Int J Gynecol Cancer. 2020. PMID: 31871115 Free PMC article.